$2.2 Billion Ohio Drug Manufacturing Campus Announced by Bayer

Bayer announced on October 2, 2026 that it plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio, describing the project as a central element of its long-term growth strategy and its commitment to innovation and patient access in its largest pharmaceuticals market.

According to Bayer’s announcement, the facility will be located in the New Albany International (AIN ) Business Park. The company expects to create around 600 high-value jobs at the site and roughly 1,500 construction jobs during the facility’s construction. The multi-year investment builds on more than seven billion dollars in U.S. pharma R&D and manufacturing spend over the past five years.

Modular Campus With First Module Expected in 2031

The flexible, modular campus is designed to combine drug substance and drug product manufacturing, leverage advanced digital and automation technologies, and support Bayer’s growing portfolio initially in oncology, cardiovascular and renal care, the company said. The first module, dedicated to drug substance manufacturing, is expected to become operational in 2031. A second module for drug product manufacturing is planned to follow in 2034.

The new site will complement Bayer’s U.S. pharmaceuticals headquarters in Whippany, New Jersey, and its other sites in Pittsburgh, Pennsylvania; Berkeley, California; Cambridge, Massachusetts; Research Triangle Park, North Carolina; and San Diego, California.

“Bayer has long seen the United States as a key manufacturing base and innovation hub. This landmark investment underscores our commitment,” said Bayer CEO Bill Anderson. “The new site will be home to manufacturing expertise and a skilled workforce that will strengthen our ability to deliver innovative, high-quality medicines to patients both in the United States and abroad.”

Sebastian Guth, Global Chief Operating Officer of Bayer Pharmaceuticals and President of Bayer U.S., called the United States a key market for the Pharmaceuticals division and the company’s fastest-growing pharmaceuticals market. He described the expansion as another important step to grow the pharmaceuticals business and to meet the demand of customers and patients in the U.S. and beyond.

Holger Weintritt, Head of Product Supply at Bayer’s Pharmaceuticals division, said the facility will be a strong strategic addition to the division’s global Product Supply network. As Bayer continues to invest in its existing manufacturing sites around the globe, he said, the planned Ohio presence will further enhance the company’s ability to serve its markets with greater resilience and reliability.

Bayer also said the site will form part of a new U.S.-based collaboration ecosystem. The ambition, the company said, is to connect cutting-edge academic innovation with advanced manufacturing expertise to create a strong ecosystem that supports future-ready pharmaceutical production.

DeWine and JobsOhio Join Announcement in Ohio

Ohio Governor Mike DeWine joined Bayer and JobsOhio on Friday to announce the plans, according to the City of New Albany. DeWine said Bayer, a globally respected life sciences company, could have chosen to build the new facility anywhere in the United States and chose Ohio. “This project firmly solidifies Ohio’s place among global biomanufacturing leaders as a destination for life sciences investment,” he said.

Senator Bernie Moreno attributed the investment to Ohio’s commitment to innovation and infrastructure and to creating an environment for businesses to succeed, saying the state beat out many others for the project. When completed, he said, the facility could employ around 600 people making medicine in Ohio.

Workforce readiness was central to Ohio’s appeal, the city said. Bayer will draw on the Ohio Life Science Training Center, now under construction and scheduled to open in summer 2027, to train Ohioans to work as biomanufacturing operators and technicians. New Albany Mayor Sloan Spalding described the center as a $38 million, state-of-the-art biomanufacturing training facility, the first of its kind in Ohio, located in the New Albany International Business Park.

JobsOhio President and CEO J.P. Nauseef said Bayer did not just choose a site but a workforce. Together, he said, JobsOhio, Ohio Life Sciences, the City of New Albany, and Columbus State are building the talent pipeline intended to ensure that the future of medicine is built in Ohio.

The city said best-in-class infrastructure and shovel-ready sites were among the reasons CNBC named Ohio the No. 1 state for business in 2026, and that two decades of strategic planning in New Albany to ensure access to power, water, and infrastructure allow projects like this one to move quickly. Bayer joins a growing life sciences cluster in the business park that includes Amgen, Hims & Hers, American Regent, and Pharmavite. Spalding said the industry employs 18,000 people across Central Ohio and 64,000 across the state, and that Bayer is expected to bring 600 additional jobs.

New Albany-Plain Local Schools Superintendent Dr. Jason Fine said the district is excited to welcome the investment and looks forward to exploring opportunities to connect education with the growing industry, expose students to future career pathways, and help them understand the skills needed for high-quality, good-paying jobs.